SML3200

MK-0608

≥98% (HPLC)

• Sinónimos: 2′-C-Methyl-7-deaza-adenosine, 4-Amino-7-(2-C-methyl-[beta]-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine, 7′DMA, 7-(2-C -Methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d ]pyrimidin-4-amine, 7-DMA, 7-Deaza-2’-C-methyladenosine, 7-Deaza-2’-CMA, 7DMA, MK 0608, MK 608, MK-608, MK0608, MK608
• Fórmula empírica (notación de Hill): C₁₂H₁₆N₄O₄
• Número de CAS: 443642-29-3
• Peso molecular: 280.28
• MDL number: MFCD14584964
• UNSPSC Code: 51111800
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D -155 to -185°, c = 1 in methanol
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• InChI: 1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1
• InChI key: IRZRJANZDIOOIF-GAJNKVMBSA-N

Descripción

Biochem/physiol Actions

MK-0608 (7DMA; 2′-C-Methyl-7-deaza-adenosine; 7-Deaza-2′-C-methyladenosine) is an orally active antiviral nucleoside analog that inhibits hepatitis C virus (HCV genotype 1b replicon IC50/90 = 0.3/1.3 ?M) and Zika virus (ZIKV strain MR766 IC50 = 1.3-9.6 μM) replication by targeting viral RNA-dependent RNA polymerase. MK-0608 effectively reduces viral load in HCV-infected (0.2-2 mg/kg chimpanzees via daily i.v. or p.o.; 3-50 mg/kg mice b.i.s. p.o.) and ZIKV-infected animals in vivo (50 mg/kg mice via daily p.o.).

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable